UBE2D1 and AL amyloidosis: DLST SLC31A1, LIPT1, and UBE2D1 are reported to regulate cuproptosis in sepsis (Wang et al., 2024), hepatocellular carcinoma (He et al., 2024), multiple myeloma (Zhu Y. et al., 2023), thyroid carcinoma (Yu et al., 2024), oral squamous cell carcinoma (Yuan et al., 2023), rheumatoid arthritis (Jiang et al., 2023), periodontitis (Liu S. et al., 2023), gastric cancer (Zhu X. et al., 2023), colorectal cancer (Yang W. et al., 2023), and myocardial infarction (Yang et al., 2024).